Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - simvastatin, quantity: 10 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; microcrystalline cellulose; purified talc; ascorbic acid; citric acid monohydrate; lactose monohydrate; magnesium stearate; butylated hydroxyanisole; titanium dioxide; hypromellose; triacetin; iron oxide red - zimstat is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. zimstat is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. zimstat is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Estats Units - anglès - NLM (National Library of Medicine)

direct rx - ezetimibe (unii: eor26lqq24) (ezetimibe - unii:eor26lqq24) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 primary hyperlipidemia monotherapy ezetimibe tablets, administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), and non-high-density lipoprotein cholesterol (non-hdl-c) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. combination therapy with hmg-coa reductase inhibitors (statins) ezetimibe tablets, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor (statin), is indicated as adjunctive therapy to die

Canadà - anglès - Health Canada

mylan pharmaceuticals ulc - atorvastatin (atorvastatin calcium) - tablet - 20mg - atorvastatin (atorvastatin calcium) 20mg - hmg-coa reductase inhibitors

Canadà - anglès - Health Canada

mylan pharmaceuticals ulc - atorvastatin (atorvastatin calcium) - tablet - 40mg - atorvastatin (atorvastatin calcium) 40mg - hmg-coa reductase inhibitors

Canadà - anglès - Health Canada

mylan pharmaceuticals ulc - atorvastatin (atorvastatin calcium) - tablet - 80mg - atorvastatin (atorvastatin calcium) 80mg - hmg-coa reductase inhibitors

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

teva b.v. - ezetimibe - tablet - 10 milligram(s) - other lipid modifying agents; ezetimibe

Canadà - anglès - Health Canada

mylan pharmaceuticals ulc - lovastatin - tablet - 20mg - lovastatin 20mg - hmg-coa reductase inhibitors

Canadà - anglès - Health Canada

mylan pharmaceuticals ulc - lovastatin - tablet - 40mg - lovastatin 40mg - hmg-coa reductase inhibitors

Canadà - anglès - Health Canada

mylan pharmaceuticals ulc - simvastatin - tablet - 5mg - simvastatin 5mg - hmg-coa reductase inhibitors

Canadà - anglès - Health Canada

mylan pharmaceuticals ulc - simvastatin - tablet - 40mg - simvastatin 40mg - hmg-coa reductase inhibitors